Pharmaceutical Market Europe • March 2026 • 27
THOUGHT LEADER
Pharma’s content paradox: why more content is not the answer
‘Content in pharma is not simply creative output – it carries scientific integrity, regulatory responsibility and commercial impact’
By Rasmus Blom
Pharma does not have a content shortage. It has a content architecture problem.
Over the last decade, our industry has invested heavily in digital transformation. New DAM platforms. New CRM systems. New review tools. New localisation workflows. Each implementation is justified. Each solves a specific need. Yet marketing excellence leaders continue to ask the same question:
Why does content still take weeks to produce?
Why does omnichannel feel operationally heavy rather than strategically empowering?
Why are we creating more assets – but seeing diminishing returns?
The answer lies not in effort, talent or ambition. It lies in fragmentation.
When systems don’t speak, organisations struggle
Most pharma companies operate in disconnected environments:
- One tool for authoring
- Another for storage
- Separate CRM platforms
- Additional systems for localisation and MLR.
Individually, they work. Collectively, they create friction.
Global teams launch materials that do not fully translate to local realities. DAM libraries overflow with assets that are technically stored but practically undiscoverable. MLR teams review entire presentations again and again instead of structured claims. Agencies are repeatedly briefed to recreate content that already exists somewhere in the system.
The result? Slow turnaround times. High agency dependency. Escalating review burden. Content that never reaches healthcare professionals (HCPs). And a growing gap between omnichannel ambition and operational capability.
The paradox is clear: we are investing more in content – yet scaling less effectively.
The hidden cost of asset thinking
A deeper issue sits beneath technology. Most organisations still approve final assets – PDFs, slide decks, email layouts – rather than structured, reusable content modules.
When an entire presentation must be reapproved because one claim changes, MLR slows. When localisation requires manual recreation rather than modular adaptation, costs multiply.
When each new channel requires a new asset build, scalability collapses.
Asset-based thinking worked in a single-channel world. It does not work in an omnichannel ecosystem.
The most forward-thinking organisations are not producing more content. They are structuring content. Modular. Searchable. Governed. Reusable.
That shift alone transforms speed, compliance and cost.
AI will not rescue fragmentation
Generative AI entered the conversation with understandable excitement. Faster drafting. Automated localisation. Personalised variations at scale.
But AI layered onto fragmented systems does not create transformation. It creates faster chaos.
AI delivers value only when the foundation is structured:
- Well-tagged, discoverable content
- Pre-approved modular claims
- Connected authoring and review workflows
- Clear, risk-stratified governance.
Without that architecture, AI becomes another disconnected tool – impressive in isolation, ineffective in execution.
The question is not whether AI belongs to pharma content. It does.
The question is whether the ecosystem is ready for it.
From fragmentation to content excellence
If we want sustainable omnichannel excellence, three capabilities must operate as one system:
- Structured, modular authoring
- Integrated approval and governance
- Connected engagement across channels.
When content moves through a connected ecosystem rather than across disconnected tools, measurable advantages emerge:
- Faster turnaround
- Reduced agency reliance
- Lower production costs
- Improved compliance confidence
- Scalable global personalisation.
Most importantly, marketing teams regain control. They move from reacting to demand to orchestrating engagement.
This is the philosophy behind integrated content ecosystems such as Anthill Cloud that bring structured content, compliant authoring and AI acceleration together within a single connected framework.
It empowers every market to create high-quality, compliant, AI-enabled content in days – not weeks – through an integrated content authoring ecosystem that streamlines content creation, accelerates approvals and enables intelligent reuse at scale.
A strategic imperative, not an IT upgrade
Content in pharma is not simply creative output. It carries scientific integrity, regulatory responsibility and commercial impact.
Fragmentation is therefore not just inefficient. It is a strategic risk.
The next era of pharma marketing will not be defined by who produces the most assets.
It will be defined by who orchestrates content most intelligently – across brands, markets, channels and systems.
The organisations that redesign their content architecture today will unlock something far more powerful than faster production.
They will unlock sustainable growth.
And in an environment where HCP expectations are rising and compliance scrutiny remains high, that is not a marketing advantage.
It is a leadership one.
References
1. Sharp, B. (2010) How Brands Grow: What Marketers Don’t Know. Oxford University Press.
2. Hurman, J. (2011) The Case for Creativity: Three Decades of Evidence of the Link Between Imaginative Marketing and Commercial Success. AUT Media.
3. DT Consulting (2024) The State of Customer Experience in the Global Pharmaceutical Industry. July 2024.
4. WARC (2025) Why CX Outperforms Paid Media in Driving Brand Growth.
Rasmus Blom is CEO at Anthill, visit www.anthill.technology/